Lumos Pharma Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lumos Pharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11279
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lumos Pharma Inc (Lumos Pharma) is a developer of novel therapies for the treatment of rare and neglected diseases. The company’s pipeline product includes LUM-001, LUM-201 and LUM-301. Its lead compound LUM001, is a small and planar molecule used for the treatment of rare disease, creatine transporter deficiency . Lumos Pharma works in collaboration with the biotechnology companies to develop new technologies for the treatment of rare diseases, through its therapeutic for rare and neglected diseases (TRND) program. The company’s TRND program provides scientific and financial support for the preclinical program to allow for the commencement of clinical trials in human subjects. Lumos Pharma is headquartered in Austin, Texas, the US.

Lumos Pharma Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lumos Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Lumos Pharma Raises USD34 Million in Series B Financing Round 10
Lumos Pharma Raises US$14 Million In Series A Financing Round 12
Licensing Agreements 13
Lumos Pharma Enters into Licensing Agreement with Ammonett Pharma 13
Lumos Pharma Inc – Key Competitors 14
Lumos Pharma Inc – Key Employees 15
Lumos Pharma Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Product News 17
05/23/2017: Ammonett Pharma Receives Positive Opinion from European Orphan Medicinal Products Committee for MK-0677 for Treatment of Pediatric Growth Hormone Deficiency 17
Product Approvals 18
Jun 19, 2017: Ammonett Pharma Granted Orphan Drug Designation From the U.S. FDA for Ibutamoren Mesylate (MK-0677) for Treatment of Growth Hormone Deficiency 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Key Facts 2
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lumos Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lumos Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lumos Pharma Raises USD34 Million in Series B Financing Round 10
Lumos Pharma Raises US$14 Million In Series A Financing Round 12
Lumos Pharma Enters into Licensing Agreement with Ammonett Pharma 13
Lumos Pharma Inc, Key Competitors 14
Lumos Pharma Inc, Key Employees 15

List of Figures
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Lumos Pharma Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Darden Restaurants, Inc.:戦略・SWOT・企業財務分析
    Darden Restaurants, Inc. - Strategy, SWOT and Corporate Finance Report Summary Darden Restaurants, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Callidus Software Inc (CALD):企業の財務・戦略的SWOT分析
    Summary Callidus Software Inc (Callidus) a subsidiary of SAP SE, operates as a technology company that offers a cloud-based customer relationship management (CRM) solutions. The company’s product portfolio includes contract life cycle management (CLM), configure price quote (CPQ) solutions, clicktoo …
  • ABM Industries Incorporated (ABM):企業の財務・戦略的SWOT分析
    ABM Industries Incorporated (ABM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • PT Central Proteina Prima Tbk (CPRO)
    PT Central Proteina Prima Tbk (CPRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Nippon Yusen Kabushiki Kaisha:企業の戦略・SWOT・財務情報
    Nippon Yusen Kabushiki Kaisha - Strategy, SWOT and Corporate Finance Report Summary Nippon Yusen Kabushiki Kaisha - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • ALTANA AG:戦略・SWOT・企業財務分析
    ALTANA AG - Strategy, SWOT and Corporate Finance Report Summary ALTANA AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Electronic Arts Inc. (EA):企業の財務・戦略的SWOT分析
    Electronic Arts Inc. (EA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Schibsted ASA:企業のM&A・事業提携・投資動向
    Schibsted ASA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Schibsted ASA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Aevi Genomic Medicine Inc (GNMX):製薬・医療:M&Aディール及び事業提携情報
    Summary Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The company provides pipeline products such as AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glut …
  • Ithaca Energy Inc. (IAE)-石油・ガス分野:企業M&A・提携分析
    Summary Ithaca Energy Inc. (Ithaca) is an oil and gas company, which explores for, develops, and produces oil and gas in the North Sea. It focuses on the appraisal and development of undeveloped discoveries and the exploitation of its existing UK producing asset portfolio. The company has a portfoli …
  • Raiffeisen Bank International AG:企業の戦略・SWOT・財務情報
    Raiffeisen Bank International AG - Strategy, SWOT and Corporate Finance Report Summary Raiffeisen Bank International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Critical Outcome Technologies Inc (COT)-製薬・医療分野:企業M&A・提携分析
    Summary Critical Outcome Technologies Inc (COTI) is a biopharmaceutical company that develops targeted therapeutics with focus on oncology. The company’s lead program COTI-2 is a novel small molecule activator of misfolded mutant p53 proteins for the treatment of ovarian and other gynecological canc …
  • Atmos Energy Corp (ATO):企業の財務・戦略的SWOT分析
    Atmos Energy Corp (ATO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • John B. Sanfilippo & Son, Inc.:企業の戦略・SWOT・財務情報
    John B. Sanfilippo & Son, Inc. - Strategy, SWOT and Corporate Finance Report Summary John B. Sanfilippo & Son, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Thryv Holdings Inc (THRY):企業の財務・戦略的SWOT分析
    Thryv Holdings Inc (THRY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • eHealthInsurance Services Inc:企業の戦略的SWOT分析
    eHealthInsurance Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Credit Agricole CIB SA:企業の戦略的SWOT分析
    Credit Agricole CIB SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Bharat Heavy Electricals Ltd (BHEL):企業の財務・戦略的SWOT分析
    Bharat Heavy Electricals Ltd (BHEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Taiwan Mobile Co., Ltd.:企業の戦略・SWOT・財務分析
    Taiwan Mobile Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Taiwan Mobile Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Avery Dennison Corporation (AVY):企業の財務・戦略的SWOT分析
    Avery Dennison Corporation (AVY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆